Nexmed Logo
 
 
Vitaros® (previously Alprox-TD)
Male erectile dysfunction ("ED") is described as the inability to attain and maintain an erection sufficient for sexual intercourse. In essence, the penis has insufficient or inadequate blood supply and the causes may be due to physiological impairment, psychological factors, or a combination of the two.
Conservative estimates suggest that 31 million men in the U.S. are affected, and more than 200 million men worldwide. The current ED treatment market is estimated at $3 billion worldwide and is projected to expand to $5 billion by year 2013.
In February 2009, NexMed sold the U.S. rights for Vitaros® to Warner Chilcott, Ltd., effectively terminating the previous licensing agreement.
   
Vitaros®
Femprox®
NM100060
   
   
 
   
 
NexMed is an emerging drug developer that is leveraging its proprietary drug delivery technology to develop a significant pipeline of innovative pharmaceutical products to address large unmet medical needs. The Company is also working with various pharmaceutical companies to explore the incorporation of NexACT® into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans and brand equity.